Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that the European ...
Cambridge researchers map the convergence of biomarkers, digital phenotyping, and AI toward biologically grounded ...